Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

FDA Approves Ustekinumab-stba for All Forms & Dosages as Its Reference Product

Michele B. Kaufman, PharmD, BCGP  |  July 16, 2025

On June 15, the U.S. Food & Drug Administration (FDA) approved a 45 mg/0.5 mL single-dose vial of ustekinumab-stba (Steqeyma) for subcutaneous injection for the treatment of plaque psoriasis or psoriatic arthritis (PsA) in pediatric patients weighing less than 60 kg and aged 6 to 17 years old.1

This approval expands the drug’s dosing flexibility for pediatric patients. Additionally, ustekinumab-stba is now available in the same dosage forms and strengths as its reference product, ustekinumab (Stelara).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA initially approved ustekinumab-stba as biosimilar to and interchangeable with ustekinumab for the same indications on Dec. 17, 2024. The agent is available for intravenous (IV) infusion and in prefilled syringes of 45 mg/0.5 mL and 90 mg/mL for subcutaneous injections.2

Ustekinumab & Its Biosimilars

Ustekinumab is a human interleukin (IL) 12 and IL-23 antagonist, anti-inflammatory agent, given by subcutaneous injection or IV infusion and administered at least every four weeks for the treatment of psoriasis and PsA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In September 2009, the FDA approved the biologics license application for ustekinumab for the treatment of adults with moderate to severe plaque psoriasis who were candidates for phototherapy or systemic therapy.3 As of November 2024, the agent was subsequently FDA approved for the treatment of adults with active PsA, moderate to severe active Crohn’s disease and/or moderate to severe active ulcerative colitis. 4

Ustekinumab is also FDA approved for the treatment of pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, and/or those with active PsA.4

In addition to ustekinumab-stba, FDA has approved six other medications as biosimilar to, and interchangeable with, ustekinumab. They are:

  • Ustekinumab-aauz (Otulfi) as a single-dose vial (45 mg/0.5 mL), prefilled syringes (45 mg/0.5 mL and 90 mg/mL) and for IV infusion;
  • Ustekinumab-ttwe (Pyzchiva) as a single-dose vial (45 mg/0.5 mL), prefilled syringes (45 mg/0.5 mL and 90 mg/mL) and for IV infusion;
  • Ustekinumab-aekn (Selarsdi) as a single-dose vial (45 mg/0.5 mL), prefilled syringes (45 mg/0.5 mL and 90 mg/mL) and for IV infusion;
  • Ustekinumab-hmny (Starjemza) as a single-dose vial (45 mg/0.5 mL), prefilled syringes (45 mg/0.5 mL and 90 mg/mL) and for IV infusion;
  • Ustekinumab-auub (Wezlana) as a single-dose vial (45 mg/0.5 mL), prefilled syringes (45 mg/0.5 mL and 90 mg/mL), auto-injectors (45 mg/0.5 mL and 90 mg/mL) and for IV infusion; and
  • Ustekinumab-kfce (Yesintek) as a single-dose vial (45 mg/0.5 mL), prefilled syringes (45 mg/0.5 mL and 90 mg/mL) and for IV infusion.5

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Celltrion announces U.S. FDA approval of additional presentation of Steqeyma (ustekinumab-stba), expanding dosing options for pediatric patients [news release]. Celltrion Inc. 2025 Jun 16.
  2. Biologics license application approval letter: Steqeyma (ustekinumab-stba). U.S. Food & Drug Administration. 2024 Dec 17.
  3. Biologics license application approval letter: Stelara (ustekinumab). U.S. Food & Drug Administration. 2009 Sep 25.
  4. Highlights of subscribing information: Stelara (ustekinumab). U.S. Food & Drug Administration. 2024 Nov.
  5. Purple Book: Database of licensed biologic products. Ustekinumab. U.S. Food & Drug Administration. 2025.

Share: 

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Biologics & BiosimilarsBiosimilarsFDAFDA approvalPsA Resource CenterPsoriasisPsoriatic Arthritisustekinumabustekinumab-stba

Related Articles
    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    May 17, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    Psoriatic Arthritis Drugs at a Glance, 2023

    April 21, 2023

    Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    FDA Approves Ustekinumab for Children with PsA

    November 7, 2022

    After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences